These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36318027)

  • 41. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
    Bashir MR; Wolfson T; Gamst AC; Fowler KJ; Ohliger M; Shah SN; Alazraki A; Trout AT; Behling C; Allende DS; Loomba R; Sanyal A; Schwimmer J; Lavine JE; Shen W; Tonascia J; Van Natta ML; Mamidipalli A; Hooker J; Kowdley KV; Middleton MS; Sirlin CB;
    J Magn Reson Imaging; 2019 May; 49(5):1456-1466. PubMed ID: 30318834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
    Harrison SA; Baum SJ; Gunn NT; Younes ZH; Kohli A; Patil R; Koziel MJ; Chera H; Zhao J; Chakravarthy MV
    Am J Gastroenterol; 2021 Dec; 116(12):2399-2409. PubMed ID: 34382947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
    Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
    Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two-dimensional Convolutional Neural Network Using Quantitative US for Noninvasive Assessment of Hepatic Steatosis in NAFLD.
    Jeon SK; Lee JM; Joo I; Yoon JH; Lee G
    Radiology; 2023 Apr; 307(1):e221510. PubMed ID: 36594835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of proton density fat fraction (PDFF) obtained from a vendor-neutral MRI sequence and MRQuantif software.
    Orcel T; Chau HT; Turlin B; Chaigneau J; Bannier E; Otal P; Frampas E; Leguen A; Boulic A; Saint-Jalmes H; Aubé C; Boursier J; Bardou-Jacquet E; Gandon Y
    Eur Radiol; 2023 Dec; 33(12):8999-9009. PubMed ID: 37402003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic resonance imaging in patients with obesity: a secondary cross-sectional study.
    Cao D; Li M; Liu Y; Jin H; Yang D; Xu H; Lv H; Liu J; Zhang P; Zhang Z; Yang Z
    BMC Med Imaging; 2022 May; 22(1):92. PubMed ID: 35581577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
    Le TA; Chen J; Changchien C; Peterson MR; Kono Y; Patton H; Cohen BL; Brenner D; Sirlin C; Loomba R;
    Hepatology; 2012 Sep; 56(3):922-32. PubMed ID: 22431131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRI.
    Colgan TJ; Van Pay AJ; Sharma SD; Mao L; Reeder SB
    J Magn Reson Imaging; 2020 Feb; 51(2):407-414. PubMed ID: 31168893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging.
    Kühn JP; Meffert P; Heske C; Kromrey ML; Schmidt CO; Mensel B; Völzke H; Lerch MM; Hernando D; Mayerle J; Reeder SB
    Radiology; 2017 Sep; 284(3):706-716. PubMed ID: 28481195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
    Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
    Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
    J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
    Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
    Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    Shen W; Middleton MS; Cunha GM; Delgado TI; Wolfson T; Gamst A; Fowler KJ; Alazraki A; Trout AT; Ohliger MA; Shah SN; Bashir MR; Kleiner DE; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Zhou J; Sirlin CB; Lavine JE
    J Hepatol; 2023 Feb; 78(2):238-246. PubMed ID: 36368598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.